Clinical Study of a Facial Cream for Rosacea

Condition(s) studied

Investigational drug(s) / intervention(s)

ARM 1: Morning/Evening: Study participants shall cleanse their entire face with water or facial cleanser. After the skin is dry, apply an appropriate amount of the investigational product cream (1-2 pumps per use) to the entire face and gently massage until absorbed.

ARM 2: Morning/Evening: Study participants shall cleanse their entire face with water or facial cleanser. After the skin is dry, apply an appropriate amount of the participants' usual non-soothing facial cream (per their regular daily usage) to the entire face and gently massage until absorbed.

Study summary

This study aimed to evaluate the efficacy, tolerability, and safety of Eucerin Skin Relief Multi-Repair Cream containing the active ingredient SenSiCel™ in improving facial rosacea. A single-center, randomized, negative-controlled clinical intervention design was adopted. A total of 76 Chinese women aged 20-50 years with Fitzpatrick skin types III-IV and mild-to-moderate rosacea (IGA score 2-3, CEA score 2-3, ≤3 inflammatory papules/pustules) were enrolled. Subjects were randomized in a 1:1 ratio into the test group (using the investigational cream) and the control group (using non-soothing daily facial cream), with an 8-week intervention period and four visits scheduled at baseline, Week 2, Week 4, and Week 8. The primary endpoint was the change from baseline in the Investigator's Global Assessment (IGA) score at Week 8. Secondary endpoints included changes in persistent erythema score, inflammatory lesion count, skin hydration, transepidermal water loss, hemoglobin index, red area proportion, and results of subject self-assessment questionnaires (Likert scale, DLQI). Tolerability and safety were also evaluated via dermatologist assessments and subject feedback. Data were analyzed using descriptive statistics, paired t-test/Wilcoxon signed-rank test, and independent t-test/Wilcoxon rank-sum test. This study provides clinical evidence for a safe and gentle adjuvant skincare regimen for patients with rosacea and offers a reference for efficacy validation of skincare products containing active ingredients.

Eligibility

Primary outcome measure(s)

• Dermatologist-Assessed Rosacea Severity — Compared with baseline, Time point at Week 2, Time point at Week 4, Time point at Week 8
  Investigator's Global Assessment (IGA) is a clinical tool that can be used to evaluate the severity of rosacea. The severity of rosacea is assessed and determined using the IGA grading scale, with scores recorded at T0 (baseline), T2w (2 weeks), T4w (4 weeks), and T8w (8 weeks).
• Dermatologist assessment of persistent erythema — Compared with baseline, Time point at Week 2, Time point at Week 4, Time point at Week 8
  The Persistent Erythema CEA Scale (0-4 points) is used to assess persistent erythema. Scoring will be performed at T0 (baseline), T2w (2 weeks), T4w (4 weeks) and T8w (8 weeks).
• Dermatologist assessment of Counting Inflammatory Lesions — Compared with baseline, Time point at Week 2, Time point at Week 4, Time point at Week 8
  Dermatologists will count facial papules and pustules of study participants at T0 (baseline), T2w (2 weeks), T4w (4 weeks) and T8w (8 weeks).
• Clinical assessment of facial TRoSA telangiectasia counts in subjects by dermatologists — Compared with baseline, Time point at Week 2, Time point at Week 4, Time point at Week 8
  Assessment of subjects' telangiectasia is conducted using the TRoSA Telangiectasia Scale (0-4 points). Scoring is performed at T0 (baseline), T2w (2 weeks), T4w (4 weeks) and T8w (8 weeks).
• Dermatologist assessment of product tolerability — Compared with baseline, Time point at Week 2, Time point at Week 4, Time point at Week 8
  Dermatologists use the safety assessment scale (0-3 points) to evaluate symptoms including edema, papules, desquamation, stinging, pruritus and burning. Assessments are performed at T0 (baseline), T2w (2 weeks), T4w (4 weeks) and T8w (8 weeks).
• Self-assessment Questionnaire — Compared with baseline, Time point at Week 2, Time point at Week 4, Time point at Week 8
  Study participants are required to complete the skin sensation self-assessment questionnaire (Likert scale) and the Dermatology Life Quality Index (DLQI) at T0 (baseline), T2w (2 weeks), T4w (4 weeks) and T8w (8 weeks).

Trial sites (1)

More ChinaNorm trials in China